🇺🇸 FDA
Patent

US 12134648

Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 12134648 (Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor) held by The Board of Regents of the University of Texas System expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61K2039/545, A61P, A61P35/00